Etzer Darout
Stock Analyst at Barclays
(4.42)
# 329
Out of 5,090 analysts
148
Total ratings
52.5%
Success rate
19.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Overweight | $28 → $36 | $27.21 | +32.30% | 10 | Nov 25, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $22 → $35 | $19.75 | +77.26% | 1 | Nov 24, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $11 → $28 | $12.02 | +132.95% | 1 | Nov 24, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $4 → $9 | $2.22 | +305.41% | 1 | Nov 24, 2025 | |
| INCY Incyte | Maintains: Overweight | $101 → $115 | $100.48 | +14.45% | 1 | Nov 24, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $44 → $45 | $45.35 | -0.77% | 7 | Nov 17, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Underweight | $25 → $21 | $29.59 | -29.03% | 2 | Nov 11, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $83 → $70 | $43.05 | +62.60% | 2 | Nov 11, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $58 → $56 | $34.40 | +62.79% | 3 | Nov 7, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $72 → $88 | $87.54 | +0.53% | 4 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $48 | $16.38 | +193.04% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $16 | $12.62 | +26.83% | 6 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $70 | $66.56 | +5.17% | 3 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $41 | $44.40 | -7.65% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $6 → $23 | $18.05 | +27.42% | 7 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $18.83 | -15.01% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $6 | $4.09 | +46.70% | 12 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $4.23 | +1,343.79% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $30.94 | +55.14% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $79.63 | +56.98% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $16 | $8.85 | +80.89% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $109.64 | +29.52% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $112 → $97 | $96.20 | +0.83% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $2.60 | +284.62% | 5 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.38 | +117.39% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $4.13 | +214.77% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $95.99 | +48.97% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $3.56 | -15.73% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $18.00 | +94.44% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.87 | +3,278.02% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $2.44 | +1,008.83% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $107.05 | +25.18% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $32.03 | +49.86% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $132.43 | -9.39% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.11 | +442.99% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $90.03 | -8.92% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.58 | +314.85% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $464.56 | -63.41% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $54.59 | -1.07% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $71.71 | -47.01% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $3.04 | +1,613.34% | 1 | Mar 28, 2018 |
Terns Pharmaceuticals
Nov 25, 2025
Maintains: Overweight
Price Target: $28 → $36
Current: $27.21
Upside: +32.30%
Syndax Pharmaceuticals
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $19.75
Upside: +77.26%
Kura Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $12.02
Upside: +132.95%
Iovance Biotherapeutics
Nov 24, 2025
Maintains: Overweight
Price Target: $4 → $9
Current: $2.22
Upside: +305.41%
Incyte
Nov 24, 2025
Maintains: Overweight
Price Target: $101 → $115
Current: $100.48
Upside: +14.45%
Scholar Rock Holding
Nov 17, 2025
Maintains: Overweight
Price Target: $44 → $45
Current: $45.35
Upside: -0.77%
Celldex Therapeutics
Nov 11, 2025
Maintains: Underweight
Price Target: $25 → $21
Current: $29.59
Upside: -29.03%
AnaptysBio
Nov 11, 2025
Maintains: Overweight
Price Target: $83 → $70
Current: $43.05
Upside: +62.60%
RAPT Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $58 → $56
Current: $34.40
Upside: +62.79%
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $72 → $88
Current: $87.54
Upside: +0.53%
Nov 7, 2025
Maintains: Overweight
Price Target: $47 → $48
Current: $16.38
Upside: +193.04%
Nov 6, 2025
Maintains: Overweight
Price Target: $15 → $16
Current: $12.62
Upside: +26.83%
Nov 5, 2025
Maintains: Overweight
Price Target: $60 → $70
Current: $66.56
Upside: +5.17%
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $40 → $41
Current: $44.40
Upside: -7.65%
Oct 29, 2025
Upgrades: Overweight
Price Target: $6 → $23
Current: $18.05
Upside: +27.42%
Oct 21, 2025
Maintains: Underweight
Price Target: $13 → $16
Current: $18.83
Upside: -15.01%
Oct 21, 2025
Maintains: Overweight
Price Target: $3.5 → $6
Current: $4.09
Upside: +46.70%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $4.23
Upside: +1,343.79%
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $30.94
Upside: +55.14%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $79.63
Upside: +56.98%
Oct 13, 2025
Initiates: Overweight
Price Target: $16
Current: $8.85
Upside: +80.89%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $109.64
Upside: +29.52%
Sep 30, 2025
Downgrades: Equal-Weight
Price Target: $112 → $97
Current: $96.20
Upside: +0.83%
Sep 23, 2025
Maintains: Overweight
Price Target: $8 → $10
Current: $2.60
Upside: +284.62%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.38
Upside: +117.39%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $4.13
Upside: +214.77%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $95.99
Upside: +48.97%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $3.56
Upside: -15.73%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $18.00
Upside: +94.44%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.87
Upside: +3,278.02%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $2.44
Upside: +1,008.83%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $107.05
Upside: +25.18%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $32.03
Upside: +49.86%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $132.43
Upside: -9.39%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.11
Upside: +442.99%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $90.03
Upside: -8.92%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.58
Upside: +314.85%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $464.56
Upside: -63.41%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $54.59
Upside: -1.07%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $71.71
Upside: -47.01%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $3.04
Upside: +1,613.34%